Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn’s Disease Using Microemulsion Formulations

Clicks: 24
ID: 309289
2025
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #15 of 15 articles by views in International Journal of Health Sciences and Engineering

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
This study evaluates mesalamine-loaded microemulsions designed to enhance drug bioavailability and site-specific delivery in the gastrointestinal (GI) tract, targeting the treatment of Crohn's disease. Mesalamine, an anti-inflammatory drug, is conventionally limited by poor solubility and inconsistent site-specific action. This research examines various microemulsion formulations to improve mesalamine delivery to the colon, assessing parameters such as stability, droplet size, encapsulation efficiency, and pH-controlled release. Optimal formulations demonstrated controlled, targeted release in colonic conditions, high stability, and minimized premature drug release in nontarget GI regions. These findings suggest potential clinical applications for advanced mesalamine therapies in Crohn's disease management.
Reference Key
imported_1761930214_6904ebe6c010a Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Suraj Mandal
Journal International Journal of Health Sciences and Engineering
Year 2025
DOI
DOI not found
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.